Macroscopic complete resection is not associated with improved survival in patients with malignant pleural mesothelioma

Batırel, Hasan Fevzi; Metintaş, Muzaffer; Çağlar, Hale Başak; Ak, Güntülü; Yumuk, Perran Fulden; Ahıskalı, Rengin; Bozkurtlar, Emine; Bekiroğlu, Nural; Laçin, Tunç; Yıldızeli, Bedrettin; Yüksel, Mustafa

doi:10.1016/j.jtcvs.2017.12.131

Cited by 18 publications

(24 citation statements)

References 25 publications

(45 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…in addition, percentage of expected forced expiratory volume in 1 second is divided into 30% to 80% and greater than 80%, likely selecting for patients with less severe disease. Finally, their series reports a 40% complete pathologic resection rate, a rate lower than that reported in the series of Batirel and associates, 10 but also with no data on tumor volume or the need to remove the diaphragm.…”

mentioning

confidence: 73%

Commentary: Biphasic malignant mesothelioma—Survival of the fittest

Felmly

Gibney

2020

The Journal of Thoracic and Cardiovascular Surgery

View full text Add to dashboard Cite

show abstract

mentioning

confidence: 73%

Commentary: Biphasic malignant mesothelioma—Survival of the fittest

Felmly

Gibney

2020

The Journal of Thoracic and Cardiovascular Surgery

View full text Add to dashboard Cite

show abstract

“…[4] Also, the coexistence of pleural and peritoneal malignant mesothelioma is extremely rare, and, to our knowledge, has been published in only one article. [4] However, peritoneal MPM after extended pleurectomy (EP) or extended pleuropneumonectomy (EPP) is considered [7] as dissemination of tumor cells in the absence of peritoneum. Otherwise, it is very difficult to prove.…”

Section: Discussionmentioning

confidence: 99%

A case of surgically treated bilateral metachronous malignant pleural mesothelioma

Bedirhan

Cansever

Yöney

et al. 2019

Turk Gogus Kalp Dama

View full text Add to dashboard Cite

Bu yazıda, hastanemize sağ plevral efüzyon ve sağ taraflı göğüs ağrısı ile kabul edilen ve torasentez ve plevral biyopsi ile malign plevral mezotelyoma tanısı konulan 59 yaşında bir erkek hasta sunuldu. Hastanın ameliyat edilebilir olduğunun belirlenmesini takiben, sağ parietal plörektomi + perikardiyal rezeksiyon + diyafragma rezeksiyonu uygulandı ve adjuvan tedavi olarak dört siklus sisplatin ve pemetreksed kombinasyonu eklendi. Hasta üç buçuk yıl boyunca herhangi bir problem olmaksızın takip edildi. Bu dönemde, sol taraflı göğüs ağrısı ve sol taraflı efüzyon fark edildi. Torasentez ve plevral biyopside tümör negatif idi. Sonra, evre 1a malign plevral mezotelyoma ile sonuçlanan video yardımlı torakoskopik cerrahi gerçekleştirildi. Torakoskopik parietal plörektomi başarıyla uygulandı. Adjuvan tedavi olarak dört siklus pemetreksed tek ajan terapisi uygulandı. Hasta tümörsüzken birinci ameliyatın 57. ve ikincisinin 21. ayında kronik obstrüktif akciğer hastalığı ve kalp yetmezliği nedeniyle öldü. Bildiğimiz kadarıyla, bu olgu literatürdeki ilk ameliyat edilmiş iki taraflı metakron primer malign plevral mezotelyomadır. Anah tar söz cük ler: Asbestozis; malign plevral mezotelyoma; plevra tümörleri; cerrahi.

show abstract

“…Surgical resection, also known as macroscopic complete resection (MCR) of tumorous mass associated with malignant mesothelioma, is one of the most common go-to interventions for its treatment; with pre-, intra-, and postoperative chemotherapy (multimodal therapy) [33]. However, surgical removal is often associated with high chances of condition relapse with as high as 77-80% chances of tumor recurrence [34,35].…”

Section: Qa Attenuates Colony Formation In Mpm Cells: Clonogenic Assaymentioning

confidence: 99%

Repurposing Quinacrine for Treatment of Malignant Mesothelioma: In-Vitro Therapeutic and Mechanistic Evaluation

Kulkarni

Vaidya

Parvathaneni

et al. 2020

IJMS

View full text Add to dashboard Cite

Malignant mesothelioma (MM) is a rare type of cancer primarily affecting mesothelial cells lining the pleural cavity. In this study, we propose to repurpose quinacrine (QA), a widely approved anti-malarial drug, for Malignant Pleural Mesothelioma (MPM) treatment. QA demonstrates high degree of cytotoxicity against both immortalized and primary patient-derived cell lines with sub-micromolar 50% inhibitory concentration (IC50) values ranging from 1.2 µM (H2452) to 5.03 µM (H28). Further, QA also inhibited cellular migration and colony formation in MPM cells, demonstrated using scratch and clonogenic assays, respectively. A 3D-spheroid cell culture experiment was performed to mimic in-vivo tumor conditions, and QA was reported to be highly effective in this simulated cellular model. Anti-angiogenic properties were also discovered for QA. Autophagy inhibition assay was performed, and results revealed that QA successfully inhibited autophagy process in MPM cells, which has been cited to be one of the survival pathways for MPM. Annexin V real-time apoptosis study revealed significant apoptotic induction in MPM cells following QA treatment. Western blots confirmed inhibition of autophagy and induction of apoptosis. These studies highlight anti-mesothelioma efficacy of QA at low doses, which can be instrumental in developing it as a stand-alone treatment strategy for MPM.

show abstract

Macroscopic complete resection is not associated with improved survival in patients with malignant pleural mesothelioma

Cited by 18 publications

References 25 publications

Commentary: Biphasic malignant mesothelioma—Survival of the fittest

Commentary: Biphasic malignant mesothelioma—Survival of the fittest

A case of surgically treated bilateral metachronous malignant pleural mesothelioma

Repurposing Quinacrine for Treatment of Malignant Mesothelioma: In-Vitro Therapeutic and Mechanistic Evaluation

Contact Info

Product

Resources

About